마우스 각막과 결막의 라이브 이미징을 위한 맞춤형 다광현미경 플랫폼

Executive Industry Relevance

This multiphoton microscopy platform enables live, label-free imaging of mouse ocular surface structures, providing critical insights into corneal and conjunctival biology for ophthalmic drug discovery. By visualizing cellular dynamics, stromal architecture, and vascular networks in vivo, the method supports mechanistic de-risking of therapeutic targets in preclinical models of ocular disease. The platform’s ability to image across the entire ocular surface with accurate positioning enhances predictive confidence in target validation and assay development pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing cell nuclei, membranes, nerve fibers, and capillaries in live ocular tissue.
• Operational Value: Supports functional target validation through real-time observation of stromal architecture via second harmonic generation and cellular dynamics in dual fluorescent reporters.
• Predictive Value: Enhances portfolio triage by providing quantitative, reproducible readouts of structural and cellular changes in disease-relevant ocular models.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream workflows by enabling high-resolution imaging of epithelial, stromal, endothelial, and vascular compartments.
• Operational Value: Addresses assay standardization and reproducibility through precise Z-stack acquisition, spectral separation of SHG and fluorescent signals, and stabilized eyeball positioning.
• Strategic Value: Highlights screening readiness and platform reuse by allowing imaging across the entire corneal and conjunctival surface with minimal phototoxicity.

Translational & Preclinical Research

• Scientific Value: Discusses disease relevance by enabling reconstruction of 3D capillary architecture in the conjunctiva and visualization of limbal epithelial layers.
• Operational Value: Describes continuity from discovery through preclinical validation by supporting intravital imaging with accurate positioning across ocular surface regions.
• Predictive Value: Addresses risk-adjusted advancement decisions by providing label-free stromal imaging and cellular mapping that inform mechanistic understanding of ocular pathology.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from early target validation through preclinical imaging, supporting hypothesis testing and mechanistic de-risking in ophthalmic research.

• Discovery Biology: Explains how the method supports hypothesis testing, pathway clarification, and biological de-risking by enabling live imaging of cellular and structural dynamics in the ocular surface.
• Screening: Describes assay readiness, reproducibility, and quantitative outputs through Z-serial imaging, spectral signal separation, and stabilized imaging conditions.
• Analytics: Highlights measurements, readouts, or statistical outputs that help teams compare conditions, including SHG for collagen architecture and tdTomato/EGFP for membrane and nuclear localization.
• Translational Research: Connects the method to preclinical continuity or biomarker alignment by enabling 3D reconstruction of capillaries and epithelial layer mapping in disease-relevant models.
• Enterprise Reuse: Frames the method as a reusable capability rather than a single-use technique, adaptable to various ophthalmic disease models and imaging endpoints.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence, target validation, reduction of mechanistic ambiguity in ocular surface biology.
• Operational Value: Standardization, reproducibility, and scalability through customized eye holder, stereotaxic staging, and controlled imaging parameters.
• Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk by enabling early visualization of target engagement and tissue response.
• Portfolio Impact: Risk-adjusted prioritization and advancement decisions through quantitative, label-free, and fluorescent readouts across corneal and conjunctival compartments.

Implementation Considerations

• Required scientific expertise in multiphoton microscopy, ocular anatomy, and transgenic model handling.
• Instrumentation and analytical infrastructure needs including titanium sapphire laser, dichroic mirrors, band pass filters, motorized stage, and 3D reconstruction software.
• Cross-team standardization requirements for imaging protocols, signal detection settings, and image processing pipelines (e.g., Fiji plugins for noise reduction and contrast enhancement).
• Adaptation considerations across model systems, including adjustment of eyelid stabilization, ocular surface coupling gel, and excitation wavelengths for different fluorescent reporters.
• Practical limitations supported by source material: stabilizing the eyeball with moderate pressure without injury is critical, as insufficient or excessive pressure compromises image quality.

Biopharma FAQs